Our data suggest that the pharmacological blockade of FPR1 exerts a potent inhibitory action on cell growth and motility; however, it also triggers resistance mechanisms by tumor cells which, through the secretion of pro-angiogenic factors, create a microenvironment that promotes cancer cells growth and, eventually, contribute to the onset of drug resistance. This evidence concerns the gene FPR1 and neoplasm.